SEIDENBERG BETH C bought KYTX
December 18, 2025 · Form 4 insider transaction
SEIDENBERG BETH C bought 133,333 shares of Kyverna Therapeutics, Inc. at $7.50 per share, a transaction worth $1000.0K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.
Footnotes
Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any.